<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ru">
	<id>https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=CRBN</id>
	<title>CRBN - История изменений</title>
	<link rel="self" type="application/atom+xml" href="https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=CRBN"/>
	<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=CRBN&amp;action=history"/>
	<updated>2026-04-20T11:14:17Z</updated>
	<subtitle>История изменений этой страницы в вики</subtitle>
	<generator>MediaWiki 1.43.6</generator>
	<entry>
		<id>https://transhumanist.ru/index.php?title=CRBN&amp;diff=6258&amp;oldid=prev</id>
		<title>OdysseusBot: Новая страница: «Protein cereblon [AD-006]  ==Publications==  {{medline-entry |title=Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and impr...»</title>
		<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=CRBN&amp;diff=6258&amp;oldid=prev"/>
		<updated>2021-05-12T15:19:50Z</updated>

		<summary type="html">&lt;p&gt;Новая страница: «Protein cereblon [AD-006]  ==Publications==  {{medline-entry |title=Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and impr...»&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Новая страница&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Protein cereblon [AD-006]&lt;br /&gt;
&lt;br /&gt;
==Publications==&lt;br /&gt;
&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/32332723&lt;br /&gt;
|abstract=Small molecules that selectively kill senescent cells (SCs), termed senolytics, have the potential to prevent and treat various age-related diseases and extend healthspan. The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity. Here, we report the use of proteolysis-targeting chimera (PROTAC) technology to reduce the platelet toxicity of navitoclax (also known as ABT263), a Bcl-2 and Bcl-xl dual inhibitor, by converting it into PZ15227 (PZ), a Bcl-xl PROTAC, which targets Bcl-xl to the cereblon ([[CRBN]]) E3 ligase for degradation. Compared to ABT263, PZ is less toxic to platelets, but equally or slightly more potent against SCs because [[CRBN]] is poorly expressed in platelets. PZ effectively clears SCs and rejuvenates tissue stem and progenitor cells in naturally aged mice without causing severe thrombocytopenia. With further improvement, Bcl-xl PROTACs have the potential to become safer and more potent senolytic agents than Bcl-xl inhibitors.&lt;br /&gt;
|mesh-terms=* Adaptor Proteins, Signal Transducing&lt;br /&gt;
* Aging&lt;br /&gt;
* Aniline Compounds&lt;br /&gt;
* Animals&lt;br /&gt;
* Blood Platelets&lt;br /&gt;
* Cell Line&lt;br /&gt;
* Cellular Senescence&lt;br /&gt;
* Female&lt;br /&gt;
* Humans&lt;br /&gt;
* Male&lt;br /&gt;
* Mice&lt;br /&gt;
* Mice, Transgenic&lt;br /&gt;
* Models, Animal&lt;br /&gt;
* Primary Cell Culture&lt;br /&gt;
* Proteolysis&lt;br /&gt;
* Sulfonamides&lt;br /&gt;
* Ubiquitin-Protein Ligases&lt;br /&gt;
* bcl-X Protein&lt;br /&gt;
&lt;br /&gt;
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181703&lt;br /&gt;
}}&lt;/div&gt;</summary>
		<author><name>OdysseusBot</name></author>
	</entry>
</feed>